December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Ruben Mesa: Honored to join many esteemed colleagues on Hematology’s Leading Experts in 2024 list by MediaMedic
Dec 3, 2024, 13:11

Ruben Mesa: Honored to join many esteemed colleagues on Hematology’s Leading Experts in 2024 list by MediaMedic

Ruben Mesa, President and Executive Director of Atrium Health Levine Cancer Institute, shared a post on LinkedIn by MediaMedic, adding:

“Honored to join many esteemed colleagues on this list! Excited this week for ASH24 to see the great advances of the American Society of Hematology!”

Quoting MediaMedic’s post:

“Honoring Hematology’s Leading Experts in 2024.

As 2024 nears its close, we take this opportunity to highlight some of the most influential hematologists whose work has shaped the field this year. From groundbreaking research to innovative treatments, these experts are transforming hematology and inspiring progress in patient care.

While this post features a selection of remarkable leaders, many more have made invaluable contributions. Upcoming posts will continue to honor all those driving advancements in hematology and improving lives worldwide.

Let’s celebrate the dedication and vision of these exceptional experts who are shaping the future of hematology.”

Ruben Mesa: Honored to join many esteemed colleagues on Hematology’s Leading Experts in 2024 list by MediaMedic

More posts featuring Ruben Mesa and MediaMedic.

Dr. Ruben A. Mesa, MD, FACP, serves as the president and executive director of Atrium Health Levine Cancer Institute (LCI) and Atrium Health Wake Forest Baptist Comprehensive Cancer Center. Additionally, he holds the position of vice dean for cancer programs and professor of medicine at Wake Forest University School of Medicine.

He is an international expert in hematologic cancers, particularly myeloproliferative neoplasms (MPNs). Through his tireless efforts, Dr. Mesa continues to drive progress in the understanding and treatment of hematologic malignancies, offering hope to those affected by these complex diseases.